Cell Replacement Therapy for Insulin-Dependent Diabetes: Maintaining Islet Architecture and Distribution After Graft.
Jacob, A., Southard, S. & Rust, W. Cell Replacement Therapy for Insulin-Dependent Diabetes: Maintaining Islet Architecture and Distribution After Graft. Curr Transpl Rep 7, 99–104 (2020).
About Seraxis, Inc.
Seraxis is a private biotechnology company launched in 2013 and located in Germantown, Maryland. The Seraxis mission is to develop a practical and potent cell replacement therapy for insulin-dependent diabetes. Our team of scientists have developed a novel cell and immune-evasion technologies that, together, reverse diabetes in animal models. We are currently working to advance this therapy to the clinic.
